Literature DB >> 21895404

Feasibility of reducing the irradiation dose in regions of active neurogenesis for prophylactic cranial irradiation in patients with small-cell lung cancer.

R Tarnawski1, L Michalecki, S Blamek, L Hawrylewicz, T Piotrowski, K Slosarek, R Kulik, B Bobek-Billewicz.   

Abstract

Prophylactic cranial irradiation (PCI) is performed on patients with limited or extensive small-cell lung cancer to reduce incidence of brain metastases and prolong survival. PCI may induce neurocognitive impairment. Decreasing irradiation of neural stem cells (NSC) might reduce PCI-induced toxicity. We tested the feasibility of reducing irradiation doses to neural stem cell (NSC) regions while maintaining prescribed doses to the planned target volume (PTV). Irradiation plans utilizing intensity-modulated radiotherapy (IMRT), helical TomoTherapy, and RapidArc for 10 consecutive lung cancer patients were evaluated. The dose distribution, dose-volume histograms, and dose homogeneity indexes were analyzed. Planned and actual dose distributions were compared by dosimetric analysis. Both helical tomotherapy and LINAC-based IMRT reduced the radiation dose to the NSC regions by approximately 45% while maintaining the full dose to the rest of brain. Measured dose distributions matched the planned dose distributions.Protecting the regions of active neurogenesis is technically feasible. Whether reducing the dose by 35% to 45% is sufficient to reduce treatment toxicity, however, can only be addressed in a randomized study. Further reducing the dose within the NSC region might also significantly decrease the dosage to the PTV.

Entities:  

Mesh:

Year:  2011        PMID: 21895404     DOI: 10.4149/neo_2011_06_507

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  7 in total

Review 1.  Hippocampus sparing in whole-brain radiotherapy. A review.

Authors:  F Oskan; U Ganswindt; S B Schwarz; F Manapov; C Belka; M Niyazi
Journal:  Strahlenther Onkol       Date:  2014-03-09       Impact factor: 3.621

2.  On the cutting edge of intensity modulated radiotherapy and simultaneous integrated boost (IMRT-SIB): The case of a patient with 8 brain metastases.

Authors:  Marica Ferro; Savino Cilla; Gabriella Macchia; Francesco Deodato; Antonio Pierro; Cinzia Digesu'; Gabriella Ferrandina; Matteo Ciuffreda; Giuseppina Sallustio; Alessio G Morganti
Journal:  Rep Pract Oncol Radiother       Date:  2014-09-23

3.  Tolerability and toxicity of prophylactic cranial irradiation in patients with non-small cell lung cancer - Results of a phase II study (with estimation of hematological toxicity, pituitary function and magnetic resonance spectra changes).

Authors:  Marzena Gawkowska-Suwińska; Sławomir Blamek; Alicja Heyda; Lukasz Boguszewicz; Anna Cichoń; Lukasz Zarudzki; Elżbieta Nowicka; Katarzyna Behrendt; Beata Smolska-Ciszewska; Grzegorz Plewicki; Aleksander Zajusz; Rafał Tarnawski
Journal:  Rep Pract Oncol Radiother       Date:  2014-07-17

4.  Dosimetric comparison of conformal technique (3D) with volumetric modulated arc therapy with respect to doses obtained in the temporal lobe area in patients irradiated for brain meningioma.

Authors:  Łukasz Trembecki; Tomasz Siudziński; Aleksandra Sztuder; Adam Maciejczyk
Journal:  Rep Pract Oncol Radiother       Date:  2019-05-31

5.  IMRT/VMAT dose distributions generated for HD ® and Millennium ® collimators TrueBeam ® and Clinac ® accelerators.

Authors:  Krzysztof Ślosarek; Iwona Brąclik; Wojciech Leszczyński; Joanna Kopczyńska; Wojciech Osewski; Jacek Wendykier
Journal:  Rep Pract Oncol Radiother       Date:  2018-10-10

6.  Intensity-modulated radiation therapy combined with concomitant temozolomide for brain metastases from lung adenocarcinoma.

Authors:  Jinli Li; Xiaoyan Chai; Ying Cao; Xiaochu Hu; Hongyu Zhu; Jianping Wang; Yiwei Wu
Journal:  Oncol Lett       Date:  2018-07-18       Impact factor: 2.967

Review 7.  [Advance of prophylactic cranial irradiation in lung cancer].

Authors:  Kan Wu; Bing Xia; Shenglin Ma
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.